Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $61.92, for a total transaction of $928,800.00. Following the transaction, the chief executive officer now owns 477,847 shares of the company's stock, valued at $29,588,286.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Grant Pickering also recently made the following trade(s):
- On Monday, March 25th, Grant Pickering sold 15,000 shares of Vaxcyte stock. The shares were sold at an average price of $66.93, for a total transaction of $1,003,950.00.
- On Friday, March 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The stock was sold at an average price of $73.70, for a total transaction of $192,799.20.
- On Thursday, February 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The stock was sold at an average price of $73.91, for a total transaction of $193,348.56.
- On Monday, January 29th, Grant Pickering sold 30,000 shares of Vaxcyte stock. The stock was sold at an average price of $66.03, for a total transaction of $1,980,900.00.
Vaxcyte Stock Down 0.4 %
The asset beating inflation by 4x
From Colonial Metals | Ad
"Trump Loophole" Beats Inflation?
Inflation has been out of control for years.
Forcing you to work longer and harder for more money that is worth less.
By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.
That's why we have released our Free Precious Metals Investment Guide that explains all the details
Shares of PCVX stock opened at $60.06 on Friday. Vaxcyte, Inc. has a 52 week low of $41.57 and a 52 week high of $82.04. The firm's 50-day simple moving average is $68.25 and its two-hundred day simple moving average is $61.27.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same period last year, the company earned ($0.73) EPS. Research analysts expect that Vaxcyte, Inc. will post -4.18 earnings per share for the current year.
Institutional Trading of Vaxcyte
Several hedge funds and other institutional investors have recently modified their holdings of the business. Raymond James & Associates raised its position in shares of Vaxcyte by 28.7% in the first quarter. Raymond James & Associates now owns 66,332 shares of the company's stock valued at $4,531,000 after purchasing an additional 14,779 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Vaxcyte by 109.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 47,388 shares of the company's stock valued at $3,237,000 after purchasing an additional 24,785 shares during the period. Banque Cantonale Vaudoise raised its position in shares of Vaxcyte by 96.7% in the first quarter. Banque Cantonale Vaudoise now owns 1,184 shares of the company's stock valued at $81,000 after purchasing an additional 582 shares during the period. PNC Financial Services Group Inc. raised its position in shares of Vaxcyte by 25.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,986 shares of the company's stock valued at $439,000 after purchasing an additional 1,411 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Vaxcyte by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 8,452,371 shares of the company's stock valued at $530,809,000 after purchasing an additional 168,125 shares during the period. Institutional investors own 96.78% of the company's stock.
Analyst Ratings Changes
Several research analysts recently weighed in on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Vaxcyte in a report on Friday, January 12th. Bank of America boosted their price target on shares of Vaxcyte from $67.00 to $80.00 and gave the stock a "buy" rating in a report on Tuesday, January 2nd. Finally, Needham & Company LLC restated a "buy" rating and set a $95.00 price target on shares of Vaxcyte in a report on Wednesday, April 10th. Four analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte has a consensus rating of "Buy" and a consensus price target of $78.50.
Read Our Latest Stock Analysis on Vaxcyte
Vaxcyte Company Profile
(
Get Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
